Market Place
Sourcing Support
XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
08 Feb 2024 //
PR NEWSWIRE
XNK Therapeutics receives EMA scientific recommendation for evencaleucel
15 Jan 2024 //
PR NEWSWIRE
XNK Therapeutics to present at DNB Nordic Healthcare Conference in Oslo
04 Dec 2023 //
PR NEWSWIRE
XNK Therapeutics to present at Investival Showcase Meeting
10 Nov 2023 //
PR NEWSWIRE
XNK Therapeutics announces poster presentations at the SITC
06 Nov 2023 //
PR NEWSWIRE
XNK Therapeutics presented two posters at the NK2023 conference in Oslo
27 Sep 2023 //
PR NEWSWIRE
XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston
28 Aug 2023 //
PR NEWSWIRE
XNK Therapeutics one of three winners of Business Sweden`s Catalyst program 2023
12 Jul 2023 //
PR NEWSWIRE
XNK Therapeutics to present at ABG Sundal Collier`s Life Science
24 May 2023 //
PR NEWSWIRE
XNK Therapeutics Enters into Research Agreement with Global Pharma Company
04 May 2023 //
PR NEWSWIRE
XNK Receives EU Tissue Establishment Certificate
03 Apr 2023 //
PR NEWSWIRE
XNK receives certificate of GMP compliance of a manufacturer from MPA
20 Mar 2023 //
PR NEWSWIRE
XNK Therapeutics appoints Dr. Peter Hovstadius as CMO
19 Jan 2023 //
PR NEWSWIRE
First patient cells collected in XNK`s preclinical bladder cancer study
15 Dec 2022 //
PRNEWSWIRE
XNK Therapeutics to use generic name evencaleucel for lead candidate
26 Sep 2022 //
PRNEWSWIRE
XNK Therapeutics appoints Dr. Anna-Karin Maltais as CSO
15 Sep 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.